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ABSTRACT
Introduction Type 2 diabetes mellitus is among the 
foremost health challenges facing policy makers in 
Thailand as its prevalence has more than tripled over 
the last two decades, accounting for considerable 
death, disability and healthcare expenditure. Diabetes 
self- management education (DSME) programmes show 
promise in improving diabetes outcomes, but this is 
not routinely used in Thailand. This study aims to test 
a culturally tailored DSME model in Thailand, using a 
three- arm cluster randomised controlled trial comparing a 
nurse- led model, a peer- assisted model and standard care. 
We will test which model is effective and cost effective to 
improve cardiovascular risk and control of blood glucose 
among people with diabetes.
Methods and analysis 21 primary care units in northern 
Thailand will be randomised to one of three interventions, 
enrolling a total of 693 patients. The primary care units 
will be randomised (1:1:1) to participate in a culturally- 
tailored DSME intervention for 12 months. The three- arm 
trial design will compare effectiveness of nurse- led, peer- 
assisted (Thai village health volunteers) and standard care. 
The primary trial outcomes are changes in haemoglobin 
A1c and cardiovascular risk score. A process evaluation 
and cost effectiveness evaluation will be conducted to 
produce policy relevant guidance for the Thai Ministry of 
Public Health. The planned trial period will start in January 
2020 and finish October 2021.
Ethics and dissemination Ethical approval has been 
obtained from Thailand and the UK. We will share our 
study data with other researchers, advertising via our 
publications and web presence. In particular, we are 
committed to sharing our findings and data with academic 
audiences in Thailand and other low- income and middle- 
income countries.
Trial registration number NCT03938233.
INTRODUCTION
Type 2 diabetes mellitus (hereto referred to as 
diabetes) is among the foremost health chal-
lenges facing policy makers in Thailand. Its 
prevalence has more than tripled over the last 
two decades to an estimated 4 million adults 
(age adjusted prevalence 7.1%) living with 
diabetes in 2015.1 2 Diabetes is associated with 
several macrovascular (eg, ischaemic heart 
disease) and microvascular complications 
(eg, nephropathy, retinopathy, neuropathy 
and foot disease), which primarily account 
for the considerable death and disability (of 
which diabetes is the fifth leading cause in 
Thailand).3 In addition, diabetes in Thai-
land causes a twofold increase in healthcare 
expenditure and significant loss of economic 
productivity—of both people with diabetes 
and their carers.1
The complications of diabetes can be 
largely prevented or delayed through lifestyle 
Strengths and limitations of this study
 ► A three- arm cluster randomised controlled trial to 
evaluate clinical and cost- effectiveness of a cultur-
ally tailored diabetes self- management education 
(DSME) under two alternative modes of delivery 
(nurse- led and peer- assisted) will provide policy 
makers with options for scalability.
 ► A culturally tailored DSME programme has been de-
veloped with input from stakeholders (policy mak-
ers, clinicians, nurses, village health volunteers and 
people with diabetes).
 ► A series of short films have been developed to intro-
duce key topics, as there is increasing recognition 
that films are a highly efficient medium for com-
municating information, particularly in low literacy 
settings.
 ► The study will be conducted in two provinces of 
Thailand, so some caution may be required when 
generalising findings to the rest of the country.
 ► Due to the nature of the intervention, blinding of par-
ticipants to their trial arm will not be possible.
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change and medication when necessary, and regular 
screening for early detection and management of compli-
cations to control risk factors such as blood glucose, 
lipids and blood pressure.4 5 Under Thailand’s universal 
health coverage, nearly everyone diagnosed with diabetes 
receives timely medical care (>97%) and has access to 
screening. Yet, surveys suggest that only about half of 
the people with diabetes achieve optimal control of risk 
factors or receive annual screening for microvascular 
complications (53%–60%).1 6 Limited data support a lack 
of engagement and self- management skills among those 
diagnosed with diabetes as the main underlying reasons 
for this.7
Successful management of diabetes involves a consid-
erable degree of self- management. People with diabetes 
need to adhere to multiple behaviours, including healthy 
lifestyles, regular monitoring and medication, problem- 
solving and healthy coping strategies. In this, they are 
greatly supported by diabetes self- management educa-
tion (DSME), defined as ‘a collaborative and ongoing 
process intended to facilitate the development of knowl-
edge, skills, and abilities that are required for successful 
self- management of diabetes’.8 Evidence from over 100 
studies, including many randomised controlled trials 
conducted predominantly in high- income countries 
(HIC), suggests that DSME programmes are associated 
with improvements in a range of behavioural outcomes 
(knowledge, behaviours, self- efficacy, psychosocial) and 
clinical outcomes (physiological risk factors, screening for 
complications, quality of life)9 10 and are cost- effective.11 
Therefore, DSME programmes are recommended by 
most clinical guidelines.8
However, there is considerable heterogeneity in the 
effectiveness of DSME programmes.9 10 Programmes 
that are more effective usually offer more than 10 hours 
of contact between trainers and patients, incorporate 
behavioural approaches and provide longer- term support 
mechanisms. However, providing intensive and sustained 
support has cost implications, resulting in ongoing efforts 
to identify more cost- efficient ways to deliver DSME, 
notably through use of lay health workers or peer educa-
tors, such as Thai village health volunteers (VHV).
Peers can support sustained changes in complex health 
behaviours by providing assistance in daily management, 
social and emotional support, linkage to clinical care and 
ongoing availability of support.12 13 Unlike the educa-
tional/psychological framework of professional support, 
peer support operates on a social support framework. 
Although traditionally restricted to those with experience 
of disease, the definition of peers has been expanded to 
include other non- professionals with a close relationship 
with the community (eg, VHV).14 However, despite wide-
spread interest, empirical data on effectiveness of peers 
in supporting behaviour change in chronic diseases, 
including diabetes, are limited and inconsistent.15 16 In an 
earlier review, the WHO did not find sufficient evidence 
to recommend peer support programmes as a policy 
option for diabetes management in low- income and 
middle- income countries (LMICs).17 Whereas many 
studies on the effectiveness of DSME programmes come 
from HIC, there is a dearth of data from LMIC settings 
on cost- effectiveness, acceptability and potential adverse 
consequences of peer support programmes as well as 
optimal strategies for mobilising and integrating peers in 
diabetes care pathways.13 18 19
In the Thai healthcare system, structured DSME is not 
routinely available. While several small- scale studies from 
Thailand have demonstrated that DSME can strengthen 
self- management of diabetes, negative perceptions of 
educational programmes and concerns about the burden 
on existing staff time and costs have so far prevented the 
introduction of DSME.1 19 However, recent policy develop-
ments in Thailand are supportive of DSME introduction, 
if a scalable model can be found. We therefore hypothe-
sise that a nurse- led and/or peer- assisted model for DSME 
delivery will be effective in improving blood glucose 
among people with diabetes, with the peer- assisted model 
being the more scalable option for the Thai healthcare 
system. We propose to evaluate this through a three- arm 
cluster randomised controlled trial.
METHODS AND ANALYSIS
Study design
This study is an Medical Research Council complex inter-
vention,20 three- arm cluster randomised controlled trial. 
Primary care units from within two provinces: Chiang Mai 
and Lampang will be randomised for patients to receive 
either the nurse- led or peer- assisted DSME intervention 
or standard care (brief education session by a nurse). 
Assessments will be undertaken at baseline, 6- month and 
12- month follow- up. A process and cost- effective evalua-
tion will also be conducted.
Setting and participant selection
Potential participants requiring a DSME intervention will 
be recruited from 21 primary care units in Chiang Mai (7 
primary care units) and Lampang provinces (14 primary 
care units) in northern Thailand. Chiang Mai is a prov-
ince of over 1.4 million people with 24 district hospitals 
and about 250 primary care units. Lampang is a province 
of approximately 700 000 people with 12 district hospi-
tals and about 140 primary care units. While diabetes is 
diagnosed at tertiary and district hospitals, it is managed 
at the primary care unit health centres, which are served 
by a full- time nurse (doctor visits weekly), and 10–15 VHV 
linking patients in the community.
From clinical records, we will recruit all new referrals 
for diabetes management and patients with uncontrolled 
diabetes diagnosed in the past 3 years at the 21 primary 
care units over a 9- month period (n=693). Posters and 
information sheets will be used to provide necessary, trial- 
related information to prospective participants (figure 1).
Participants presenting to one of the 21 primary care 
units will be included if they are:
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1. over 18 years of age with a new referral for type 2 dia-
betes management;
2. Over 18 years of age with uncontrolled diabetes 
(HbA1c>7 %) within the first 3 years of diagnosis; will-
ing and able to attend educational group meetings and
3. available for 6- month and 12- month follow- up visits.
Participants will be excluded if they:
1. have advanced diabetic complications such as diabetic 
nephropathy, diabetic retinopathy or amputations; or 
if they are pregnant as patients with these conditions 
and comorbidities are usually referred to secondary 
care facilities for treatment in Thailand and not often 
managed in primary care where this trial is conducted,
2. have learning disabilities, dementia or active severe 
mental illness or
3. lack the capacity to give voluntary, informed consent.
Randomisation
Stratified by province, 21 primary care units (7 from 
Chiang Mai and 14 from Lampang) will be randomised to 
provide one of three interventions: (1) nurse- led DSME; 
(2) nurse- led DSME with peer assistance (provided by 
Thai VHV) or (3) standard care (brief education session 
by a nurse), resulting in seven primary care units in each 
arm of the study. All primary care units follow protocols 
for diabetes management as outlined by national guide-
lines. Stratification by province will minimise any varia-
tion in practice between the different primary care units.
Sample size calculation
The trial is powered to detect a difference in HbA1c of 
0.6% (SD 1.5%) between control and intervention arms, 
based on the effect size of 0.6% noted in a previous 
diabetes management study in Thailand,21 and the fact 
that an increase in HbA1c of ~0.5% was associated with 
increased mortality among people with diabetes.22 An 
intraclass correlation coefficient between primary care 
units of 0.02 was assumed based on a similar study which 
found that the intraclass correlation for HbA1c at 3 years 
was 0.02 (95% CI 0.00 to 0.08).23 Allowing for a loss- to- 
follow up rate of 20%, 693 participants are needed from 
21 primary care units (7 in each trial arm arm) to achieve 
80% power at 2.5% significance level.
Informed consent
Written informed consent will be obtained from all study 
participants in Thai before any study procedures are 
undertaken including enrolment, intervention alloca-
tion, follow- up interviews and blood draws. Local research 
assistants will explain the study to patients using the 
patient information sheet (see online supplemental file). 
The right of the patient to refuse to participate without 
giving reasons will be respected.
Intervention description and delivery
The DSME programme has been developed using a struc-
tured process. This included a desk and literature review 
and focus groups with local nurses and VHV to develop a 
paper prototype of the intervention, including a hypoth-
esised pathway of action (eg, common- sense model of 
illness, empowerment, discovery learning, social learning 
and social support) and a training manual for nurses and 
VHV. In addition, seven brief films (5–6 min long) have 
been developed and have been used to trigger discussions 
Figure 1 Trial flow diagram.
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on key topic areas during DSME intervention meetings 
covering such topics as medical adherence, dietary 
recommendation, physical activity and stress manage-
ment. Films will be used in the intervention as they are 
increasingly recognised as a highly effective medium for 
improved recall when communicating large amounts of 
information, particularly in low literacy settings.24 Films 
will be in the local language and use local people.
Our DSME programme will consist of four modules. 
Module 1 covers the general overview of diabetes, treat-
ment targets and goal setting. Module 2 covers diet and 
nutrition. Module 3 covers physical activity and exercise, 
while module 4 covers stress management and mental 
health. Each module takes approximately 1.5 hours. Each 
participant is given an information and self- assessment 
booklet which covers all content and materials for the 
four modules.
In addition to routine care, in the nurse- led arm, the 
nurse will deliver the DSME to groups of 5–10 partici-
pants per session within the first months after enrolment. 
The participants in the nurse- led arm will also be given 
a refresher session going over all four modules again at 
6 months after enrolment. For the peer- assisted arm, a 
VHV will participate as an assistant to the nurse in the first 
DSME session. However, the VHV will lead the refresher 
course at 6 months. In addition, participants in the peer- 
assisted arm will receive monthly contact with the VHV 
either via a home visit or telephone call. During these 
brief 15–20 min monthly contacts, VHV will ask about 
the progress made, providing encouragement if plans for 
self- management are being followed or discussing ways to 
overcome barriers and set new goals if obstacles are iden-
tified. Contents of the three trial arms are summarised in 
table 1.
The intervention will be piloted at four community 
primary care units with four nurses and four VHV who 
will be trained to deliver the DSME programme to 
groups of 5–10 persons with diabetes. This will allow for 
refining the intervention, ensuring data collection can 
be completed as specified, and to check our assumptions 
and processes for the trial. For the main trial, a 2- day 
workshop will be held such that at least one nurse and 
one VHV from each primary care unit will be trained by 
the Thai research team to deliver the DSME programme 
at the community primary care unit or neighbourhoods 
as appropriate. The trial coordinator will conduct peri-
odic site visits as additional training as requested and a 
line of communication will be established between the 
research team and each site to answer any issues which 
may arise.
A process evaluation using qualitative methods will 
be conducted during the trial period and at the end of 
the study. Observations including video recordings of 
intervention delivery will be made. We plan to conduct 
5–10 focus groups among providers (nurses and VHV) to 
explore healthcare professionals’ perspectives regarding 
their experience and implementation of the DSME 
programme, including views on the cultural transfer-
ability of DSME and scalability to the Thai context. In 
addition, we plan to conduct 20 structured interviews with 
patients. These evaluations will help assess intervention 
delivery (fidelity, dose and reach), clarify causal mecha-
nisms (those hypothesised by theory of change developed 
within the project or emergent mechanisms identified) 
and detail contextual factors (barriers, facilitators) associ-
ated with variation in outcomes.25 The process evaluation 
will also consist of one- to- one interviews with clinicians 
and policymakers and direct observations of patients. 
Data for economic evaluations (resource usage and 
quality of life using EQ- 5D)26 will be obtained prospec-
tively alongside the trial.
Standard care
Patients in the control group will receive standard care 
in the form of a brief didactic educational session at the 
time of diagnosis of diabetes and during routine clinic 
visits at 6 months.27
Study outcomes
The two primary outcomes of the intervention are a 
difference in trial arms at 1- year follow- up in HbA1c and 
cardiovascular risk score. There is a growing recognition 
of the importance of combining tight glycaemic control 
with reduction in other cardiovascular risk factors for 
prevention of or reduction in complications.5 The cardio-
vascular risk will be estimated by the Thai cardiovascular 
risk score model, which estimates the risk of dying from 
any cardiovascular disease over 10 years based on age, 
gender, smoking habits, total cholesterol and systolic 
blood pressure, as it has been calibrated for use in a Thai 
population.28
Additional secondary outcomes include changes at 
1 year for biological, physical, psychosocial, lifestyle and 
intervention- related measures, as described in table 2.
Table 1 Summary of DSME delivery in the three trial arms
Month
Routine 
care Nurse- led DSME
Peer- assisted 
DSME*
0 Individual 
session
Nurse provides 
DSME (four 
modules)
Nurse provides 
DSME (four 
modules) with 
VHV to assist the 
sessions
6 Individual 
session
Refresher course 
(four modules) 
provided by nurse
Refresher course 
(four modules) led 
by VHV
12 Outcome 
assessment
Outcome 
assessment
Outcome 
assessment
*Participants in the peer- assistant arm will additionally receive 
monthly contact with the VHV either via a home visit or telephone 
call.
DSME, diabetes self- management education; VHV, village health 
volunteer.
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Data collection and follow-up
Each participant will be involved in the study for 12 
months after taking consent and baseline data. The trial 
is expected to start January 2020 and finish October 2021.
Data collection methods will include:
Questionnaires
Questionnaire data will be collected face- to- face by 
research assistants for the full sample at baseline, 6 and 12 
months at the community primary care unit where partic-
ipants are recruited. A custom- designed form linked to 
RedCap will be used to collect, validate, verify and store 
respondents’ data where possible or else data will be 
collected via paper forms and double- entered into the 
databases. All data files and databases will be password 
protected.
Biological samples
Blood samples will be collected at baseline, 6 and 12 
months, to measure fasting blood glucose, HbA1c and 
lipids, coordinating where possible with the annual 
routine tests offered to patients to reduce duplication. All 
blood samples will be administered from participants by 
trained phlebotomists. Data will be linked to the partici-
pant information using a unique respondent ID, which 
will be assigned to all study participants.
Interviews
During the delivery of the intervention, a process evalua-
tion using a subset of participants will be conducted using 
in- depth interviews and focus group discussions. These will 
be audio- recorded. Data will be collected using a range of 
qualitative methods: (a) one- to- one interviews and focus 
Table 2 Summary of primary and secondary outcome measures
Measures or questionnaires
Primary outcomes
Haemoglobin A1c 
levels (HbA1c)
HbA1c will measure the average blood glucose (sugar) levels over the past 2–3 months
Thai Cardiovascular 
risk score
Estimates the risk of dying from any cardiovascular disease over 10 years based on age, gender, 
smoking habits, total cholesterol and systolic blood pressure.
Secondary outcomes
Biological and 
physical measures
Body weight, body mass index; blood lipids (total, LDL- C HDL, triglycerides), waist circumference, 
blood pressure, fasting blood glucose
Quality of life WHOQOL- BREF. A 26- item questionnaire developed by WHO to assess quality of life in adults29
The European Quality of life questionnaire (EuroQol EQ- 5D 5L).26 EQ- 5D is a quality of life measure that 
includes five quality of life questions on mobility, self- care, usual activity, pain, anxiety/depression and a 
scale of 0–100 on how the person is feeling on that day.
Depression Hospital Anxiety and Depression Scale (HADS).30 HADS measures depression and anxiety that will 
address psychological change with a scale from 0 to 3.
Stress Perceived Stress Questionnaire (PSS).31 PSS is a psychological instrument for measuring the perception 
of stress. Ten items with a scale from 1 to 4.
Physical activity International Physical Activity Questionnaire (IPAQ).32 Short form IPAQ is an assessment of physical 
activity comprising of seven questions. There are two forms of output from scoring the IPAQ. Results 
can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as 
a continuous variable (MET- minutes a week). MET- minutes represent the amount of energy expended 
carrying out physical activity.
Diabetes knowledge 
and skills
Brief diabetes Illness Perception Questionnaire (B- IPQ).33 B- IPQ has nine components of which the first 
five questions assess the cognitive representation of illness perception, two of the questions assess the 
emotional representation, one item assesses comprehensibility and one item on the root cause of the 
illness
Diabetes Self- Management Education and Support (DMSES).34 DMSES is one of the most widely used 
scale in measuring self- efficacy in type 2 diabetes management. The Thai- DMSES has 20 questions 
which has been demonstrated to have good psychometric properties35
Summary of Diabetes Self- Care Activities questionnaire (SDSCA).36 SDSCA is a diabetes self- care 
activities questionnaire focusing on general diet, diabetes- specific diet, physical activity, blood- glucose 
testing, foot care and smoking.
Satisfaction with 
intervention
Chronic Illness Resources Survey (CIRS).37 CIRS is a questionnaire to represent patient’s received 
support. Individual’s support for behavioural- specific disease management is assessed: proximal 
support, for example, friend and family and distal factor for example, neighbourhood or community.
Modified Medical Interview Satisfaction Scale (MISS-21).38 MISS-21 is a questionnaire to measure 
patient satisfaction with patient and healthcare professional communication/consultation.
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group discussions with nurses, health volunteers, people 
with diabetes and their carers (5–10 focus groups and 20 
semistructured interviews) and (b) ethnography through 
direct observations including video recordings of inter-
vention delivery and unstructured interviews with clinical 
managers and policy makers. The data collected will be 
used to capture the range of experiences of the inter-
vention and identify unanticipated pathways to generate 
new theories as well as exploring the scalability of the 
intervention.
Trial follow-up appointments
The research team will hold weekly briefings with the study 
coordinators to generate a list of priority areas and loss 
to follow- up participant lists. Arrangements to follow- up 
participants who have not turned up for their appoint-
ment will be made, with attempts to contact participants 
through SMS, phone calls or house visits. Participants will 
be declared lost to follow- up if they do not show for a 
month and are untraceable.
Data management
A data collection protocol will be developed, and the 
study coordinator in Thailand will provide training to 
fieldworkers before data collection commences. Vali-
dation will be performed on a random sample of ques-
tionnaire data by crosschecking with clinic records. Any 
discrepancies will be followed- up and addressed by field 
workers, recontacting participants to clarify as neces-
sary. Using Redcap (https:// redcap. med. cmu. ac. th), 
quantitative data will be entered directly via a form with 
built- in data checks to minimise transcription errors (or 
where necessary collected on paper and later double 
entered into the electronic form). Postentry checks will 
be conducted by exploring the distribution, ranges and 
outliers of each variable. All hospital laboratories have 
their own internal quality assurance protocols and are 
also linked to a national external quality assurance mech-
anism. Fieldworkers will be trained in qualitative methods 
and an interview schedule will be devised.
Statistical analysis
Quantitative analysis
Available outcome data will be analysed on an intention- 
to- treat basis. Potential clustering of outcomes (HbA1c 
at 12 months and cardiovascular disease risk score at 12 
months) at the level of community primary care units 
will be accounted for using random intercept models. 
To improve precision of the estimates, outcomes will 
be adjusted for their baseline values. In case of baseline 
imbalances of relevant covariates (eg, age, education 
level, body mass index), judged by statistical significance 
at p<0.05, we will conduct a secondary analysis adjusting 
for these covariates.
Qualitative analysis
Qualitative data from interviews, focus groups and 
direct observations will be transcribed and analysed 
using NVivo software. The data will be analysed using 
a descriptive, phenomenological approach to under-
stand participants’ experiences and interpret them 
within their respective cultural contexts. Comparative 
analysis will compare and contrast these themes across 
participants. Deviant cases will be actively sought 
throughout the analysis and emerging ideas and 
themes modified in response. In addition, thematic 
analysis will be used to inform elements of scalability 
and to produce a set of considerations in making deci-
sions about the scalability of the intervention.
Cost-effective analysis
Data for economic evaluation (resource usage and quality 
of life using EQ- 5D) will be obtained prospectively along-
side the trial. We will aim to capture all health service 
contacts, as well as out- of- pocket expenses and medica-
tion use. Educator training costs will be included, as well 
as minimal intervention material costs (as most will be 
made available freely after the trial). Utility values from 
EQ- 5D will be derived using a Thai tariff. Incremental 
cost utility will be estimated from the Thai health system 
and societal perspectives to provide incremental cost- 
effectiveness ratio and probability of being cost- effective 
at Thai government’s willingness to pay threshold of 
160 000 baht/QALY.
ETHICS AND DISSEMINATION
This study is to be conducted according to the inter-
national standards of Good Clinical Practice (Inter-
national Conference on Harmonization guidelines), 
Declaration of Helsinki and International Ethical 
Guidelines for Biomedical Research Involving Human 
Subjects, applicable national government regulations 
and institutional research policies and procedures. 
All investigators received Good Clinical Practice 
training at the onset of the study. Ethical approval was 
obtained prior to start of the project from Chiang Mai 
University (No. 326/2018) and the London School of 
Hygiene & Tropical Medicine (16113/RR/12850). The 
study protocol, informed consent form, patient infor-
mation sheet and other relevant information has been 
approved. Any future amendments of the protocol 
shall be submitted to and approved by the Institu-
tional Review Board (IRB) before implementation.
Trial monitoring and oversight
The role of the Trial Steering Committee (TSC) is to 
provide overall supervision of the trial. The TSC will meet 
every 6 months. The TSC will include experts in the field 
of DSME, health psychology and clinical trials as well as 
an independent Chair.
Dissemination
Research findings will be disseminated to scientific audi-
ences at major conferences and published in high- impact, 
open- access scientific journals; planned publications 
include those on intervention development, primary trial 
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results, process evaluation and health systems analysis, 
at a minimum. This study is expected to have a major 
policy impact due to the close involvement of a key policy 
maker in the project. Towards the end of the study, a 
dedicated workshop will be held with key governmental 
stakeholders to disseminate the recommended model for 
DSME implementation in Thailand and encourage inclu-
sion of a large- scale scientific evaluation into any national 
implementation of the scheme.
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